HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
BörsenkürzelHSCS
Name des UnternehmensHeartSciences Inc
IPO-datumJun 15, 2022
CEOMr. Andrew Simpson
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeJun 15
Addresse550 Reserve St, Suite 360
StadtSOUTHLAKE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl76092
Telefon16822377781
Websitehttps://heartsciences.com/
BörsenkürzelHSCS
IPO-datumJun 15, 2022
CEOMr. Andrew Simpson
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten